Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer - Kirschbrown, Whitney. P. (Clinical Pharmacology. Genentech Research and Early Development) ; Wang, B. (Clinical Pharmacology. Genentech Research and Early Development) ; Nijem, I. (Clinical Pharmacology. Genentech Research and Early Development) ; Ohtsu, A. (Department of Gastrointestinal Oncology. National Cancer Center Hospital East) ; Hoff, P. M. (Instituto do Câncer de São Paulo. Faculdade de Medicina da Universidade de São Paulo) ; Shah, M. A. (Medical Oncology/Solid Tumor Program. Sandra and Edward Meyer Cancer Center. Weill Cornell Medical College) ; Shen, L. (Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing). Department of Gastrointestinal Oncology. Peking University Cancer Hospital and Institute) ; Kang, Y. K. (Department of Oncology. Asan Medical Center. University of Ulsan College of Medicine) ; Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ; Girish, S. (Clinical Pharmacology. Genentech Research and Early Development) ; Garg, Amit (Clinical Pharmacology. Genentech Research and Early Development) ; Universitat Autònoma de Barcelona